Cite
Nirvanappa AC, Mohan CD, Rangappa S, et al. Correction: Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo. PLoS One. 2017;12(4):e0175659doi: 10.1371/journal.pone.0175659.
Nirvanappa, A. C., Mohan, C. D., Rangappa, S., Ananda, H., Sukhorukov, A. Y., Shanmugam, M. K., Sundaram, M. S., Nayaka, S. C., Girish, K. S., Chinnathambi, A., Zayed, M. E., Alharbi, S. A., Sethi, G., Basappa, & Rangappa, K. S. (2017). Correction: Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo. PloS one, 12(4), e0175659. https://doi.org/10.1371/journal.pone.0175659
Nirvanappa, Anilkumar C, et al. "Correction: Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo." PloS one vol. 12,4 (2017): e0175659. doi: https://doi.org/10.1371/journal.pone.0175659
Nirvanappa AC, Mohan CD, Rangappa S, Ananda H, Sukhorukov AY, Shanmugam MK, Sundaram MS, Nayaka SC, Girish KS, Chinnathambi A, Zayed ME, Alharbi SA, Sethi G, Basappa, Rangappa KS. Correction: Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo. PLoS One. 2017 Apr 06;12(4):e0175659. doi: 10.1371/journal.pone.0175659. eCollection 2017. PMID: 28384360; PMCID: PMC5383341.
Copy
Download .nbib